BTG2 overexpression increases the radiosensitivity of breast cancer cells in vitro and in vivo

Oncology Research

Volumn 20, Issue 10, 2013, Pages 457-465

  Hu, Xudong ^a,b   Xing, Ligang ^a   Jiao, Yang ^c   Xu, Jiaying ^c   Wang, Xingwu ^a   Han, Anqin ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

B cell translocation gene; Breast cancer; Member 2 (BTG2); Radiosensitivity; Xenograft

Indexed keywords

CYCLIN B1; CYCLIN D1; LIPOCORTIN 5; PROTEIN BAX; PROTEIN P53; XRCC1 PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; BTG2 GENE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA DAMAGE; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; X IRRADIATION;

EID: 84883036837     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504013X13685487925211     Document Type: Article

References (28)

1. Rouault, J. P.; Falette, N.; Guehenneux, F.; Guillot, C.; Rimokh, R.; Wang, Q.; Berthet, C.; Moyret-Lalle, C.; Savatier, P.; Pain, B.; Shaw, P.; Berger, R.; Samarut, J.; Magaud, J. P.; Ozturk, M.; Samarut, C.; Puisieux, A. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat. Genet. 14:482-486; 1996.
2. Duriez, C.; Falette, N.; Audoynaud, C.; Moyret-Lalle, C.; Bensaad, K.; Courtois, S.; Wang, Q.; Soussi, T.; Puisieux, A. The human BTG2/TIS21/PC3 gene: Genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene 282:207-214; 2002.
3. Lim, I. K. TIS21 (/BTG2/PC3) as a link between ageing and cancer: Cell cycle regulator and endogenous cell death molecule. J. Cancer Res. Clin. Oncol. 132:417-426; 2006.
4. Duriez, C.; Moyret-Lalle, C.; Falette, N.; El-Ghissassi, F.; Puisieux, A. BTG2, its family and its tutor. Bull. Cancer 91:E242-E253; 2004.
5. Zhang, L.; Huang, H.; Wu, K.; Wang, M.; Wu, B. Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. Mol. Biol. Rep. 37:2579-2586; 2010.
6. Hata, K.; Nishijima, K.; Mizuguchi, J. Role for Btg1 and Btg2 in growth arrest of WEHI-231 cells through arginine methylation following membrane immunoglobulin engagement. Exp. Cell Res. 313:2356-2366; 2007.
7. Takahashi, F.; Chiba, N.; Tajima, K.; Hayashida, T.; Shimada, T.; Takahashi, M.; Moriyama, H.; Brachtel, E.; Edelman, E. J.; Ramaswamy, S.; Maheswaran, S. Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene 30:3084-3095; 2011.
8. Kawakubo, H.; Carey, J. L.; Brachtel, E.; Gupta, V.; Green, J. E.; Walden, P. D.; Maheswaran, S. Expression of the NF-κB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene 23:8310-8319; 2004.
9. Fu, F.; Zhao, M.; Yang, Y. J.; Tong, G. Z.; Yang, B. F.; Song, C.; Li, X. Antiproliferative effect of newcastle disease virus strain D90 on human lung cancer cell line A549. Oncol. Res. 19:323-333; 2011.
10. Slaoui, M.; Fiette, L. Histopathology procedures: From tissue sampling to histopathological evaluation. Methods Mol. Biol. 691:69-82; 2011.
11. Kwon, Y. K.; Jun, J. M.; Shin, S. W.; Cho, J. W.; Suh, S. I. Curcumin decreases cell proliferation rates through BTG2-mediated cyclin D1 downregulation in U937 cells. Int. J. Oncol. 26:1597-1603; 2005.
12. Ryu, M. S.; Lee, M. S.; Hong, J. W.; Hahn, T. R.; Moon, E.; Lim, I. K. TIS21/BTG2/PC3 is expressed through PKCdelta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression. Exp. Cell Res. 299:159-170; 2004.
13. Boiko, A. D.; Porteous, S.; Razorenova, O. V.; Krivokrysenko, V. I.; Williams, B. R.; Gudkov, A. V. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Rasinduced transformation. Genes Dev. 20:236-252; 2006.
14. Goldschneider, D.; Million, K.; Meiller, A.; Haddada, H.; Puisieux, A.; Benard, J.; May, E.; Douc-Rasy, S. The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells. J. Cell Sci. 118:1245-1253; 2005.
15. Mollerstrom, E.; Kovacs, A.; Lovgren, K.; Nemes, S.; Delle, U.; Danielsson, A.; Parris, T.; Brennan, D. J.; Jirstrom, K.; Karlsson, P.; Helou, K. Upregulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray. BMC Cancer 10:296; 2010.
16. Kawakubo, H.; Brachtel, E.; Hayashida, T.; Yeo, G.; Kish, J.; Muzikansky, A.; Walden, P. D.; Maheswaran, S. Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res. 66:7075-7082; 2006.
17. Park, T. J.; Kim, J. Y.; Oh, S. P.; Kang, S. Y.; Kim, B. W.; Wang, H. J.; Song, K. Y.; Kim, H. C.; Lim, I. K. TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop. Hepatology 47:1533-1543; 2008.
18. Wei, S.; Hao, C.; Li, X.; Zhao, H.; Chen, J.; Zhou, Q. Effects of BTG2 on proliferation inhibition and anti-invasion in human lungcancer cells. Tumour Biol. 33:1223-1230; 2012.
19. Evangelisti, C.; Astolfi, A.; Gaboardi, G. C.; Tazzari, P.; Pession, A.; Goto, K.; Martelli, A. M. Tis21/btg2/pc3 and cyclin d1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest. Cell. Signal. 21:801-809; 2009.
20. Buganim, Y.; Solomon, H.; Rais, Y.; Kistner, D.; Nachmany, I.; Brait, M.; Madar, S.; Goldstein, I.; Kalo, E.; Adam, N.; Gordin, M.; Rivlin, N.; Kogan, I.; Brosh, R.; Sefadia-Elad, G.; Goldfinger, N.; Sidransky, D.; Kloog, Y.; Rotter, V. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res. 70:2274-2284; 2010.
21. Tachiiri, S.; Katagiri, T.; Tsunoda, T.; Oya, N.; Hiraoka, M.; Nakamura, Y. Analysis of gene-expression profiles after gamma irradiation of normal human fibroblasts. Int. J. Radiat. Oncol. Biol. Phys. 64:272-279; 2006.
22. Krause, K.; Wasner, M.; Reinhard, W.; Haugwitz, U.; Dohna, C. L.; Mossner, J.; Engeland, K. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res. 28:4410-4418; 2000.
23. Rocha, S.; Martin, A. M.; Meek, D. W.; Perkins, N. D. p53 Represses cyclin D1 transcription through downregulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with histone deacetylase 1. Mol. Cell. Biol. 23:4713-4727; 2003.
24. Epand, R. F.; Martinou, J. C.; Montessuit, S.; Epand, R. M. Transbilayer lipid diffusion promoted by Bax: Implications for apoptosis. Biochemistry 42:14576-14582; 2003.
25. Wei, C.; Skopp, R.; Takata, M.; Takeda, S.; Price, C. M. Effects of double-strand break repair proteins on vertebrate telomere structure. Nucleic Acids Res. 30:2862-2870; 2002.
26. Yoshikawa, Y.; Yasui, H. Zinc complexes developed as metallopharmaceutics for treating diabetes mellitus based on the biomedicinal inorganic chemistry. Curr. Top. Med. Chem. 12:210-218; 2012.
27. Levy, N.; Oehlmann, M.; Delalande, F.; Nasheuer, H. P.; Van Dorsselaer, A.; Schreiber, V.; de Murcia, G.; Menissier-de, M. J.; Maiorano, D.; Bresson, A. XRCC1 interacts with the p58 subunit of DNA Pol α-primase and may coordinate DNA repair and replication during S phase. Nucleic Acids Res. 37:3177-3188; 2009.
28. Grasby, J. A.; Finger, L. D.; Tsutakawa, S. E.; Atack, J. M.; Tainer, J. A. Unpairing and gating: Sequence-independent substrate recognition by FEN superfamily nucleases. Trends Biochem. Sci. 37:74-84; 2012.